Annolyse
BriefingsCompaniesInsightsPrinciplesCompareChatWatchlist

Explore

  • Briefings
  • Companies
  • Insights
  • Compare

Resources

  • Search
  • Methodology

© 2026 Annolyse.

←Back to companies

RUA · NZX

Rua Bioscience (RUA)

Healthcare / Medicinal cannabis•Covered: HY22 - HY26•7 published briefings

Rua Bioscience is an NZX-listed healthcare / medicinal cannabis company with HY22 - HY26 of published result briefings.

Latest briefing

HY26 · Released 27 February 2026

Revenue grew to NZ$1.3m but losses persisted as borrowings quadrupled

A 4.5x step-up in debt funded most of the cash uplift while total assets sit below the supplied historical range.

Market data

Latest available
Price
NZD 0.03
Mkt cap
$10.2m
Yield
0%

Quote as of 04-06-2026 2:50pm NZT

Sections⌄
  1. Snapshot
  2. Chat
  3. Longitudinal View
  4. Follow-through
  5. Archive
  6. Related Insights
  1. Snapshot
  2. Chat
  3. Longitudinal View
  4. Follow-through
  5. Archive
  6. Related Insights

Snapshot

Latest metrics

HY26, released 27 February 2026

← Swipe to view more
RUA latest metrics
MetricValueChange
Revenue$1.3m↑ +7747.1%
Operating profit-$1.7m↑ +84.9%
NPAT-$1.8m↑ +83.5%
Operating cash flow-$1.5m↑ +28.7%
OCF / Operating profit %92.0%↑ +72.5pp
Net debt-$0.4m↑ +50.5%
Net debt / Operating profit0.24x↑ +242.9%
ROE %-59.3%↑ +55.2pp
PBT-$1.8m↑ +83.5%
Debtor days51—

Source: latest published briefing (HY26, released 27 February 2026). Change compares against the prior equivalent period: HY24, released 29 February 2024.

Chat

Ask about RUA

Ask follow-up questions about Rua Bioscience's latest result and company history.

Informational only. No buy, sell, hold, price-target, or personal financial advice.

Ask about RUA

Informational only. No buy, sell, hold, price-target, or personal financial advice.

Sign in to chat

Sign in to ask company questions.

What changed in the latest result?What is unusual in the historical context?How has cash conversion changed over time?Compare this company with CNU.

Checking account...

Longitudinal view

Performance over time

The latest period is shown first.

← Swipe to view more
RUA metric history
MetricHY266 MONTHS27 February 2026FY2512 MONTHS1 September 2025HY246 MONTHS29 February 2024FY2312 MONTHS29 August 2023HY236 MONTHS28 February 2023FY2212 MONTHS29 August 2022HY226 MONTHS25 February 2022Trend
Revenue$1.3m$1.9m$0.02m$6.5m$0.25m$0.65m$360m
Chart
Revenue growth %92.2%490.6%-100.0%910.8%-29.4%43.2%33.8%
Chart
Operating profit-$1.7m-$3.3m-$10.9m-$6.1m$0.63m-$7.6m-$3.9m
Chart
Operating profit margin %-123.8%-173.6%n/m-94.0%248.0%n/m-1.1%
Chart
PBT-$1.8m-$3.5m-$10.9m-$6m$0.7m-$7.5m-$3.5m
Chart
NPAT-$1.8m-$3.5m-$10.9m-$6m$0.7m-$8.6m-$2.5m
Chart
Operating cash flow-$1.5m-$2.8m-$2.1m-$5.9m-$3.7m-$6.8m-$3.7m
Chart
OCF / Operating profit %92.0%84.5%19.5%96.4%-581.6%90.3%96.1%
Chart
FCF pre-lease—-$2.8m-$2.1m-$6m-$3.7m-$7.2m-$4m
Chart
FCF post-lease—-$2.8m—-$6m———
Chart
DPS——0.0c————
—
ROE %-59.3%-70.6%-114.5%-29.6%2.7%Outside range highOutside range high roe. 2.7%; 3-period range -114.5% to -9.3%. ROE: 2.7%, above normal range; 3-period mean -61.0%, range -114.5%--9.3%.-32.6%-9.3%
Chart
  • HY23 ROE %: Outside range high roe. 2.7%; 3-period range -114.5% to -9.3%. ROE: 2.7%, above normal range; 3-period mean -61.0%, range -114.5%--9.3%.
  • HY24 ROE %: Outside range low roe. -114.5%; 3-period range -59.3% to 2.7%. ROE: -114.5%, below normal range; 3-period mean -22.0%, range -59.3%-2.7%.
Net debt-$0.4m$0.48m-$0.8m——-$1.9m-$2.3m
Chart
Net debt / Operating profit0.24x-0.15x0.07x——0.25x0.58x
Chart
Debtor days5141—6———
Chart
Inventory days9378534611981240
Chart
Total assets$8.7m$6.8m$10m$21m$29.1m$33.6m$28m
Chart

Reference: annolyse.ai/companies/rua

Note: Figures are shown as reported. Half-year and full-year absolute values are not directly comparable. Growth rates and ratios are the meaningful comparison across mixed periods.

Operating working-capital movement

Per-period working-capital absorption or release, from the same published history. Positive values are working-capital build; negative values are release.

↗
Loading chart...

The setup & the reality

FY25 → HY26 Follow-through

The latest result is checked against what the prior briefing said to watch.

Current result now available

HY26 · Released 27 February 2026

Revenue grew to NZ$1.3m but losses persisted as borrowings quadrupled

A 4.5x step-up in debt funded most of the cash uplift while total assets sit below the supplied historical range.

Read latest briefing→

Historical setup

What FY25 said to watch

From RUA revenue rose 490.6% but the business remains deeply cash-negative

No formal targets were provided and no forward guidance was quantified. The release notes strong momentum expected to continue into FY26 and references expanded markets including Germany and the UK. The H2 revenue run-rate of NZD 1.2m, if sustained, would imply an annualised revenue approaching NZD 2.4m, though that would still fall well short of the level needed to approach cash breakeven given the current cost base.

The central uncertainty is whether revenue growth can outpace cash consumption quickly enough to avoid further dilutive capital raises. The trajectory is improving, but the gap between revenue and cash breakeven remains large relative to available liquidity.

Open questions

Open questions from FY25

  • What is the gross margin on commercial sales, and at what revenue level does the business reach operating cash breakeven?
  • How long does the current cash and debt facility cover operating outflows, and has additional funding been secured or committed since 30 June 2025?
  • What is the customer and geographic concentration behind the NZD 1.5m in commercial revenue, and does any single market or customer represent a material proportion?
  • Whether the German and UK market expansions mentioned in the release are generating revenue or are still pre-revenue, and what investment they require.
  • Can the H2 cash burn rate of NZD 0.8m be maintained or further reduced as revenue scales, or were there one-off timing benefits in H2?

This briefing cannot assess pipeline optionality, regulatory approval timelines, or the probability of achieving cash-flow breakeven without disclosed cost-structure detail and forward revenue commitments.

Archive

Briefing archive

Every published Annolyse briefing for this company appears here in reverse chronological order.

HY26 · Released 27 February 2026

Revenue grew to NZ$1.3m but losses persisted as borrowings quadrupled

A 4.5x step-up in debt funded most of the cash uplift while total assets sit below the supplied historical range.

Read briefing→

FY25 · Released 1 September 2025

RUA revenue rose 490.6% but the business remains deeply cash-negative

Strong commercial momentum cut the loss before tax by 74.8%, yet cash fell to NZD 0.2m and operating outflows persist, making runway the central

Read briefing→

HY24 · Released 29 February 2024

Goodwill impairment of $8.3m drives HY24 loss of $10.9m

Management writes off a prior acquisition that failed to deliver, leaving a $1.0m cash buffer and ongoing operating burn.

Read briefing→

FY23 · Released 29 August 2023

Customer revenue $0.4m as cash burn $5.9m leaves $2.5m on hand

Headline revenue of $6.5m is dominated by fair value gains on contingent consideration; commercial revenue remains immaterial against ongoing burn.

Read briefing→

HY23 · Released 28 February 2023

Reported $0.7m profit masks unchanged $3.7m cash burn against $1.7m balance

Non-cash items drove the swing to NPAT while operating cash outflow held near prior levels and the cash balance fell 24.5%.

Read briefing→

FY22 · Released 29 August 2022

Cash falls to $1.9m as operating burn widens to $6.8m

First product sales arrived but losses widened materially, leaving only months of cash at the current operating burn rate.

Read briefing→

HY22 · Released 25 February 2022

Operating cash burn nearly doubled to $3.7m before first revenue

Headline cash fell from $19.2m to $2.3m as Rua moves to commercialisation, with the loss widening only modestly.

Read briefing→

Related insights

Compare this company

The latest RUA metrics also appear in these cross-company views.

Insight

Revenue growth context

Revenue growth was 92.2% for this reporting period.

Open insight→

Insight

Earnings quality and statutory distortions

PBT and NPAT growth diverged by 0.0pp.

Open insight→

Insight

ROE and capital efficiency

ROE was -59.3%, +5.3pp versus the prior comparable period.

Open insight→

Insight

Working-capital pressure

Inventory days were 93 days, +8 days versus the prior comparable period.

Open insight→

Get notified when RUA publishes

Get the next Rua Bioscience result briefing and five-year history updates by email.